A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2001
10/11/2001	WO2000050633A9 Method for cloning signal transduction intermediates
10/11/2001	WO2000048606A9 Compositions and methods for use in targeting vascular destruction
10/11/2001	WO2000042429A3 In vitro model for gastrointestinal inflammation
10/11/2001	WO2000017176A3 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
10/11/2001	US20010029304 Cyclopentane heptan (ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
10/11/2001	US20010029303 Total synthesis of antitumor acylfulvenes
10/11/2001	US20010029298 Novel intermediates in the synthesis of camptothecin and related compounds and synthesis thereof
10/11/2001	US20010029264 In mixture with vitamin e, dimethylisosorbide, citric acid and polyoxyethylene glycol
10/11/2001	US20010029250 Antiinflammatory agents; anticarcinogenic agents
10/11/2001	US20010029249 Adenovirus comprising a gene coding for glutathione peroxidase
10/11/2001	US20010029246 Antiproliferative agent
10/11/2001	US20010029043 Prokaryotic; transformed with nucleic acid encoding papillomavirus virus major capsid protein that assembles within, such as Salmonella, to form chimeric virus like particles; anticancer, antitumor vaccine
10/11/2001	US20010029020 In vitro determination of metastatic stomach, esophageal, and colorectal cancer from sampling cells outside of the colorectal track for gene transcript or protein
10/11/2001	US20010029019 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
10/11/2001	US20010028879 Inhibition of graft versus host disease
10/11/2001	EP1145001A3 (in vitro) model for gastrointestinal inflammation
10/11/2001	DE10110455A1 Sensitizer for tumor treatment contains a xanthene dye structure and a structure with at least one hydrophilic group and at least one lipophilic group bound to one and the same carbon atom in the molecule
10/11/2001	DE10015836A1 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
10/11/2001	DE10015814A1 Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung Medicines to stimulate leukopoiesis, for the treatment of tumors and protozoal diseases and process for its preparation
10/11/2001	CA2421464A1 Combined interferon alfa and liposomal-encapsulated all-trans retinoic acid, including preparation and use
10/11/2001	CA2413211A1 A gene differentially expressed in breast and bladder cancer and encoded polypeptides
10/11/2001	CA2405549A1 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcription coupled repair genes
10/11/2001	CA2405319A1 Methods and compositions for modulating integrin-mediated cell-cell interactions
10/11/2001	CA2405299A1 Method of treatment using ligand-immunogen conjugates
10/11/2001	CA2404965A1 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
10/11/2001	CA2404665A1 Novel compounds for enhancing chemotherapy
10/11/2001	CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001	CA2404576A1 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability
10/11/2001	CA2404526A1 Protein amf-1 to amf-10 and nucleic acids encoding the same
10/11/2001	CA2404519A1 Wnt-7b-like polypeptides and nucleic acids encoding same
10/11/2001	CA2404501A1 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
10/11/2001	CA2404484A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis
10/11/2001	CA2404365A1 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
10/11/2001	CA2404300A1 Medical devices suitable for gene therapy regimens
10/11/2001	CA2404291A1 Butylnitrone containing compositons for inhibition of cancer development
10/11/2001	CA2404257A1 Novel protein, dna thereof and process for producing the same
10/11/2001	CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001	CA2404040A1 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
10/11/2001	CA2403998A1 Mucin-1 specific binding members and methods of use thereof
10/11/2001	CA2403964A1 Compositions and methods for dendritic cell-based immunotherapy
10/11/2001	CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001	CA2403735A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
10/11/2001	CA2403608A1 Use of fulvestrant in the treatment of resistant breast cancer
10/11/2001	CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001	CA2403242A1 Binding peptides for carcinoembryonic antigen (cea)
10/11/2001	CA2402864A1 D and l etherlipid stereoisomers and liposomes
10/11/2001	CA2402586A1 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001	CA2402539A1 Combination therapies with vascular damaging activity
10/11/2001	CA2402078A1 Divided dose therapies with vascular damaging activity
10/11/2001	CA2401948A1 Cd20/ige-receptor like molecules and uses thereof
10/11/2001	CA2401854A1 Therapeutic combinations of antihypertensive and antiangiogenic agents
10/11/2001	CA2401104A1 Method for treating cells resistant to antineoplastic agents
10/11/2001	CA2397203A1 Phosphoramidate prodrugs
10/10/2001	EP1143001A1 Novel interferon-alpha
10/10/2001	EP1142905A1 Novel depsipeptide compound
10/10/2001	EP1142902A2 3'-Derivatised oligonucleotide analogues with non-nucleotidic groups, their preparation and use
10/10/2001	EP1142900A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same
10/10/2001	EP1142893A1 Substituted O6-benzylguanines and 6(4)-benzyloxypyrimidines
10/10/2001	EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001	EP1142578A1 Method for producing an antitumoral agent and antitumoral agent thus obtained
10/10/2001	EP1141728A1 Kidney disease detection and treatment
10/10/2001	EP1141723A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists
10/10/2001	EP1141389A2 Reagents and methods useful for detecting diseases of the breast
10/10/2001	EP1141376A1 Peptidoglycan recognition proteins
10/10/2001	EP1141364A1 Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
10/10/2001	EP1141362A1 Gene transfer vector for the diagnosis and therapy of malign tumors
10/10/2001	EP1141357A1 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
10/10/2001	EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001	EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
10/10/2001	EP1141338A1 Recombinant herpes simplex virus useful for treating neoplastic disease
10/10/2001	EP1141332A1 Human cyclic nucleotide pdes
10/10/2001	EP1141331A2 HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
10/10/2001	EP1141326A2 Human akt-3
10/10/2001	EP1141318A2 P450 / acetaminophen gdept for cancer treatment
10/10/2001	EP1141296A2 Interferon-epsilon
10/10/2001	EP1141290A2 Compositions and methods for therapy and diagnosis of ovarian cancer
10/10/2001	EP1141288A2 Lymphocytic membrane proteins
10/10/2001	EP1141287A1 Pancreatic polypeptide zsig66
10/10/2001	EP1141284A2 Methods and compositions for inhibiting neoplastic cell growth
10/10/2001	EP1141280A1 Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors
10/10/2001	EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001	EP1141277A2 Antisense oligonucleotide for inhibiting the expression of the adhesion molecule very late antigen 4 (vla-4) in human cells
10/10/2001	EP1141274A2 Soluble receptor br43x2 and methods of using them for therapy
10/10/2001	EP1141266A2 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
10/10/2001	EP1141246A2 Non-myeloablative tolerogenic treatment
10/10/2001	EP1141241A2 Astrocytes, their preparation and uses thereof
10/10/2001	EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001	EP1141235A2 (bifidobacterium) in the treatment of inflammatory disease
10/10/2001	EP1141079A1 Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
10/10/2001	EP1141028A2 Human monoclonal antibodies to ctla-4
10/10/2001	EP1141027A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
10/10/2001	EP1141024A2 Polypeptide variants with altered effector function
10/10/2001	EP1141019A2 Substance for producing highly effective anti-tumour medicaments and corresponding method
10/10/2001	EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001	EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001	EP1141009A2 Reagents and methods useful for detecting diseases of the breast
10/10/2001	EP1141007A1 Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
10/10/2001	EP1141006A1 Topoisomerase ii inhibitor
10/10/2001	EP1141003A1 Methods
10/10/2001	EP1141002A1 Human cervical cancer 1 protooncogene and protein encoded therein

1 ... 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 ... 2211